Researchers are exploring a new treatment called laromestrocel (Lomecel-B) for infants with Hypoplastic Left Heart Syndrome (HLHS), a serious heart condition. In a recent meeting with the U.S. Food and Drug Administration (FDA), Longeveron Inc. discussed the Phase 2b ELPIS II trial, which aims to assess the effectiveness of this therapy as an additional treatment option. The FDA recognizes HLHS as a rare disease with significant unmet needs, but they raised concerns about the trial’s current focus on measuring right ventricle ejection fraction, stating it may not adequately show the treatment’s effectiveness.

For families with infants diagnosed with HLHS, this research could lead to better treatment options that improve heart function and overall outcomes. The FDA has suggested that more objective measures, such as overall survival rates and the need for heart transplants, should be included in the trial’s evaluation. This could provide clearer insights into how well laromestrocel works in improving the health of these infants.

Currently, the ELPIS II trial is still in the early stages, and the FDA has shifted its stance, no longer considering it pivotal at this time. The trial is still blinded, meaning that neither the researchers nor the participants know who is receiving the treatment. While the interim analysis is ongoing, Longeveron is working to refine their primary endpoint to align with the FDA’s recommendations. The results from this trial are expected to be released in August 2026, which will provide more information about the potential benefits of this treatment for infants with HLHS.

Source: longevity.technology